ERBB2 and breast carcinoma: Notably, trastuzumab-dkst achieved the distinction of being the initial FDA-approved trastuzumab biosimilar.[28,135] In HER2-positive breast cancer metastases treatment, paclitaxel combined with trastuzumab and pertuzumab is typically the initial therapy.